Biocon has received an Establishment Inspection Report (EIR) from the USFDA for its Biologics Drug Product facility in Bengaluru, stating the inspection is closed.
Biocon had undergone a surveillance (routine) cGMP inspection of this Drug Product facility in Bengaluru from 22 August to 30 August 2019.
The receipt of EIR indicates a successful closure of this inspection.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)